Below is a compiled list of scientific research and studies on Cannabidiol (CBD) and it’s potential use for treating Digestive Issues.
Colitis and Crohn’s
- Cannabidiol in inflammatory bowel diseases: a brief overview.
- Cannabidiol Reduces Intestinal Inflammation through the Control of Neuroimmune Axis
- Cannabis finds its way into treatment of Crohn’s disease
- Cannabidiol, a safe and non-psychotropic ingredient of the marijuana plant Cannabis sativa, is protective in a murine model of colitis.
- Cannabinoids and the gut: new developments and emerging concepts.
- Topical and Systemic Cannabidiol Improves Trinitrobenzene Sulfonic Acid Colitis in Mice
- The effects of Δ9-tetrahydrocannabinol and cannabidiol alone and in combination on damage, inflammation and in vitro motility disturbances in rat colitis
- Hergenrather presents study of Crohn’s patients as a template for clinical research on Cannabis
- Low-Dose Cannabidiol Is Safe but Not Effective in the Treatment for Crohn’s Disease, a Randomized Controlled Trial
- Manipulation of the endocannabinoid system in colitis: A comprehensive review
Irritable Bowel Syndrome
- Cannabinoids and gastrointestinal motility: animal and human studies.
- The role of the endocannabinoid system in the brain-gut axis
- Endocannabinoids and the gastrointestinal tract.
- Cannabinoids and the gut: New developments and emerging concepts
- Cannabidiol Reduces Intestinal Inflammation through the Control of Neuroimmune Axis
- Cannabinoid actions at TRPV channels: effects on TRPV3 and TRPV4 and their potential relevance to gastrointestinal inflammation.
- Clinical endocannabinoid deficiency (CECD): can this concept explain therapeutic benefits of cannabis in migraine, fibromyalgia, irritable bowel syndrome and other treatment-resistant conditions?
- Therapeutic potential of cannabinoid-based drugs.
- Beneficial effect of the non-psychotropic plant cannabinoid cannabigerol on experimental inflammatory bowel disease
